1
|
Current methods for the detection of Plasmodium parasite species infecting humans. CURRENT RESEARCH IN PARASITOLOGY & VECTOR-BORNE DISEASES 2022; 2:100086. [PMID: 35434694 PMCID: PMC9006665 DOI: 10.1016/j.crpvbd.2022.100086] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/29/2022] [Revised: 03/10/2022] [Accepted: 03/11/2022] [Indexed: 11/23/2022]
Abstract
Malaria is the world’s fatal parasitic disease. The ability to quickly and accurately identify malaria infection in challenging environments is crucial to allow efficient administration of the best treatment regime for human patients. If those techniques are accessible and efficient, global detection of Plasmodium species will become more sensitive, allowing faster and more precise action to be taken for disease control strategies. Recent advances in technology have enhanced our ability to diagnose different species of Plasmodium parasites with greater sensitivity and specificity. This literature review provides a summary and discussion of the current methods for the diagnosis and identification of Plasmodium spp. in human blood samples. So far not a single method is precise, but advanced technologies give consistent identification of a Plasmodium infection in endemic regions. By using the power of the recent methods, we can provide a broader understanding of the multiplicity of infection and or transmission dynamics of Plasmodium spp. This will result in improved disease control strategies, better-informed policy, and effective treatment for malaria-positive patients. Summary of the methods currently available for the detection of Plasmodium spp. infecting humans. No single method is perfect for every application to identify Plasmodium spp. Newly developed methods give promise for more reliable characterisation of Plasmodium spp.
Collapse
|
2
|
van den Hoogen LL, Bareng P, Alves J, Reyes R, Macalinao M, Rodrigues JM, Fernandes JM, Goméz LF, Hall T, Singh SK, Fornace K, Luchavez J, Kitchen A, Chiodini P, Espino F, Tetteh KKA, Stresman G, Sepúlveda N, Drakeley C. Comparison of Commercial ELISA Kits to Confirm the Absence of Transmission in Malaria Elimination Settings. Front Public Health 2020; 8:480. [PMID: 33014975 PMCID: PMC7509087 DOI: 10.3389/fpubh.2020.00480] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Accepted: 07/28/2020] [Indexed: 11/13/2022] Open
Abstract
Background: Antimalarial antibody measurements are useful because they reflect historical and recent exposure to malaria. As such, they may provide additional information to assess ongoing transmission in low endemic or pre-elimination settings where cases are rare. In addition, the absence of antibody responses in certain individuals can indicate the cessation of transmission. Commercial malaria enzyme-linked immunosorbent assays (ELISA) detect antimalarial antibodies and are commonly used to screen blood donations for possible malaria infection. However, there is no standardized test to detect antimalarial antibodies for epidemiological use. Here we compared five commercially available ELISA kits (Trinity Biotech, newbio, DiaPro, Cellabs, and NovaTec) in search of a standardized tool for supporting claims of absence of malaria transmission. For comparison, a research-based (RB) ELISA protocol was performed alongside the commercial kits. Results: The commercial kits were first compared using serum samples from known malaria-unexposed individuals (n = 223) and Toxoplasma-infected individuals (n = 191) to assess specificity and cross-reactivity against non-malaria infections. In addition, 134 samples from ≥10-year-olds collected in a hyperendemic region in the Gambia in the early 1990s were used to assess sensitivity. Three out of five kits showed high sensitivity (90–92%), high specificity (98–99%), low cross-reactivity (0–3%) and were considered user-friendly (Trinity Biotech, newbio and NovaTec). Two of these kits (Trinity Biotech and NovaTec) were taken forward for epidemiological evaluation and results were compared to those using the RB-ELISA. Samples from two pre-elimination settings (Praia, Cape Verde; n = 1,396, and Bataan, the Philippines; n = 1,824) were tested. Serological results from both the Trinity Biotech kit and the RB-ELISA concurred with recent passively detected case counts in both settings. Results from the Trinity Biotech kit reflected a significant decrease in the number of reported cases in Bataan in the 1990s better than the RB-ELISA. Results from the NovaTec kit did not reflect transmission patterns in either setting. Conclusion: The Trinity Biotech commercial ELISA kit was considered reliable for epidemiological use and accurately described transmission patterns in two (previously) malaria endemic settings. The use of this simple and standardized serological tool may aid national control and elimination programs by confirming that regions are free from malaria.
Collapse
Affiliation(s)
- Lotus L van den Hoogen
- Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Paolo Bareng
- Department of Health, Research Institute for Tropical Medicine, Manila, Philippines
| | - Joana Alves
- National Institute of Public Health, Praia, Cape Verde
| | - Ralph Reyes
- Department of Health, Research Institute for Tropical Medicine, Manila, Philippines
| | - Malou Macalinao
- Department of Health, Research Institute for Tropical Medicine, Manila, Philippines
| | | | - José M Fernandes
- Faculty of Science and Technology, University of Cape Verde, Praia, Cape Verde
| | - Lara F Goméz
- Department of Natural, Life and Environmental Sciences, Jean Piaget University of Cape Verde, Praia, Cape Verde
| | - Tom Hall
- Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Susheel K Singh
- Department of Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark.,Department of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, Copenhagen, Denmark
| | - Kimberly Fornace
- Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Jennifer Luchavez
- Department of Health, Research Institute for Tropical Medicine, Manila, Philippines
| | - Alan Kitchen
- NHS Blood and Transplant, London, United Kingdom
| | - Peter Chiodini
- Hospital for Tropical Diseases and London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Fe Espino
- Department of Health, Research Institute for Tropical Medicine, Manila, Philippines
| | - Kevin K A Tetteh
- Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Gillian Stresman
- Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Nuno Sepúlveda
- Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom.,Centre of Statistics and Applications, University of Lisbon, Lisbon, Portugal
| | - Chris Drakeley
- Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom
| |
Collapse
|
3
|
Zakeri S, van den Hoogen LL, Mehrizi AA, Karimi F, Raeisi A, Drakeley C. Anti-malarial seroprevalence assessment during an elimination programme in Chabahar District, south-eastern Iran. Malar J 2016; 15:382. [PMID: 27448606 PMCID: PMC4957887 DOI: 10.1186/s12936-016-1432-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2016] [Accepted: 07/06/2016] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND Iran has achieved a substantial decline in malaria incidence over the past decades. A common feature of malaria-endemic settings is the requirement for more sensitive techniques to describe levels of low transmission. In this study, serological and parasitological methods were used to measure transmission levels of Plasmodium falciparum and Plasmodium vivax during an elimination programme (2012) in Chabahar District, Sistan and Baluchistan Province, south-eastern Iran. METHODS Participants were randomly selected from 64 different geographical clusters in Chabahar city and surrounding villages. Antibody responses to P. falciparum and P. vivax blood-stage antigens were assessed by ELISA, while microscopy and molecular testing were used to determine parasite carriage by species. Age-adjusted antibody responses were analysed using a reversible catalytic model to calculate seroconversion rates (SCR). RESULTS There was no evidence of recent transmission in the study areas, indicated by an absence of parasite infections in all ages and low or absent serological responses to either species in young children. The best model for age P. falciparum seroconversion was one with a change in exposure 21 years before sampling was done in Chabahar city (P = 0.018) and 4 years in the villages (P = 0.039). There was a higher level of recent P. vivax transmission compared to P. falciparum, based on the SCRs, in both the city and village settings. CONCLUSION Serological analysis identified a decline in P. falciparum transmission in the urban areas of Chabahar, consistent with a previously described decrease in malaria in the early 1990s, demonstrating the utility of this approach to reconstruct exposure history. At present, it remains unclear whether the P. vivax antibody responses reflect active transmission due to new infections or relapse infections. The absence of parasitological and serological evidence of recent malaria transmission in Chabahar District is viable evidence for certification of elimination.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Antibodies, Protozoan/blood
- Child
- Child, Preschool
- Cross-Sectional Studies
- DNA, Protozoan/analysis
- DNA, Protozoan/genetics
- Disease Eradication
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Iran/epidemiology
- Malaria, Falciparum/epidemiology
- Malaria, Falciparum/immunology
- Malaria, Falciparum/parasitology
- Malaria, Vivax/epidemiology
- Malaria, Vivax/immunology
- Malaria, Vivax/parasitology
- Male
- Microscopy
- Middle Aged
- Plasmodium falciparum/immunology
- Plasmodium falciparum/isolation & purification
- Plasmodium vivax/immunology
- Plasmodium vivax/isolation & purification
- Polymerase Chain Reaction
- Seroepidemiologic Studies
- Urban Population
- Young Adult
Collapse
Affiliation(s)
- Sedigheh Zakeri
- />Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BCR), Pasteur Institute, P.O. Box: 1316943551, Tehran, Iran
| | | | - Akram Abouie Mehrizi
- />Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BCR), Pasteur Institute, P.O. Box: 1316943551, Tehran, Iran
| | - Fatemh Karimi
- />Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BCR), Pasteur Institute, P.O. Box: 1316943551, Tehran, Iran
| | - Ahmad Raeisi
- />National Programme Manager for Malaria Control, Ministry of Health and Medical Education, Tehran, Iran
- />School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| | - Chris Drakeley
- />Department of Immunology and Infection, London School of Hygiene & Tropical Medicine, London, UK
| |
Collapse
|
4
|
Cho SJ, Lee J, Lee HJ, Jo HY, Sinniah M, Kim HY, Chong CK, Song HO. A Novel Malaria Pf/Pv Ab Rapid Diagnostic Test Using a Differential Diagnostic Marker Identified by Network Biology. Int J Biol Sci 2016; 12:824-35. [PMID: 27313496 PMCID: PMC4910601 DOI: 10.7150/ijbs.14408] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2015] [Accepted: 05/06/2016] [Indexed: 11/05/2022] Open
Abstract
Rapid diagnostic tests (RDTs) can detect anti-malaria antibodies in human blood. As they can detect parasite infection at the low parasite density, they are useful in endemic areas where light infection and/or re-infection of parasites are common. Thus, malaria antibody tests can be used for screening bloods in blood banks to prevent transfusion-transmitted malaria (TTM), an emerging problem in malaria endemic areas. However, only a few malaria antibody tests are available in the microwell-based assay format and these are not suitable for field application. A novel malaria antibody (Ab)-based RDT using a differential diagnostic marker for falciparum and vivax malaria was developed as a suitable high-throughput assay that is sensitive and practical for blood screening. The marker, merozoite surface protein 1 (MSP1) was discovered by generation of a Plasmodium-specific network and the hierarchical organization of modularity in the network. Clinical evaluation revealed that the novel Malaria Pf/Pv Ab RDT shows improved sensitivity (98%) and specificity (99.7%) compared with the performance of a commercial kit, SD BioLine Malaria P.f/P.v (95.1% sensitivity and 99.1% specificity). The novel Malaria Pf/Pv Ab RDT has potential for use as a cost-effective blood-screening tool for malaria and in turn, reduces TTM risk in endemic areas.
Collapse
Affiliation(s)
- Sung Jin Cho
- 1. Department of Bioinformatics, College of Natural Sciences, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea
| | - Jihoo Lee
- 2. Department of Biochemistry, College of Natural Sciences, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea
| | - Hyun Jae Lee
- 1. Department of Bioinformatics, College of Natural Sciences, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea
| | - Hyun-Young Jo
- 3. Laboratory Medicine, Chungbuk National University Hospital, Cheongju, Chungbuk, Republic of Korea
| | | | - Hak-Yong Kim
- 2. Department of Biochemistry, College of Natural Sciences, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea
| | - Chom-Kyu Chong
- 5. GenBody Inc., Dankook Biotech Business IC, Cheonan, Chungnam, Republic of Korea
| | - Hyun-Ok Song
- 6. Department of Infection Biology, Wonkwang University School of Medicine, Iksan, Jeonbuk, Republic of Korea
| |
Collapse
|
5
|
Kim J, Jang JW, Kim JY, Oh DJ, Lim CS. Combined Use of Malaria Antigen and Antibody Enzyme-Linked Immunosorbent Assay for Blood Screening of Plasmodium vivax in the Republic of Korea. Med Princ Pract 2016; 25:212-8. [PMID: 26794404 PMCID: PMC5588392 DOI: 10.1159/000444144] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/19/2015] [Accepted: 01/20/2016] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVE To evaluate the clinical sensitivity and specificity of the newly developed Genedia malaria antigen enzyme-linked immunosorbent assay (ELISA) test and to evaluate the diagnostic efficiency of the combined use of the Genedia malaria antigen and antibody ELISA tests to detect Plasmodium vivax in blood samples. MATERIALS AND METHODS In all, 1,070 samples were analyzed: 300 P. vivax-infected patients, 41 samples from posttreatment patients upon follow-up and 729 healthy volunteers. The Genedia malaria antigen ELISA test and the Genedia malaria antibody ELISA 2.0 test were evaluated and compared to polymerase chain reaction and microscopy. RESULTS The Genedia malaria antigen ELISA test had a clinical sensitivity of 94.7% (284/300) and a clinical specificity of 99.3% (724/729). The Genedia malaria antibody ELISA 2.0 test had a clinical sensitivity of 94.0% (282/300) and a clinical specificity of 98.4% (717/729). The Genedia malaria antigen ELISA test was able to detect 13 confirmed P. vivax cases without antibodies against P. vivax, whereas the Genedia malaria antibody ELISA 2.0 test detected 11 confirmed P. vivax cases nonreactive to the Genedia malaria antigen ELISA test, and 25 cases from 41 follow-up samples nonreactive in the Genedia malaria antigen ELISA test. The combined Genedia malaria antigen and antibody ELISA 2.0 tests had a clinical sensitivity of 98.3% (295/300) and a clinical specificity of 97.9% (714/729). CONCLUSION The combination of antigen and antibody ELISAs improved the diagnostic sensitivity in P. vivax-confirmed cases in the Republic of Korea.
Collapse
Affiliation(s)
- Jeeyong Kim
- Department of Laboratory Medicine, Brain Korea 21 Graduate School of Medicine, College of Medicine, Korea University, Seoul, Republic of Korea
| | - Jin Woo Jang
- Department of Laboratory Medicine, Brain Korea 21 Graduate School of Medicine, College of Medicine, Korea University, Seoul, Republic of Korea
| | - Ju Yeon Kim
- Department of Laboratory Medicine, Brain Korea 21 Graduate School of Medicine, College of Medicine, Korea University, Seoul, Republic of Korea
| | - Deok Ja Oh
- Central Blood Laboratory Center, Korean Red Cross, Seoul, Republic of Korea
| | - Chae Seung Lim
- Department of Laboratory Medicine, Brain Korea 21 Graduate School of Medicine, College of Medicine, Korea University, Seoul, Republic of Korea
- *Chae Seung Lim, Department of Laboratory Medicine, College of Medicine, Korea University Guro Hospital, Guro 2 Dong, Guro Gu, Seoul 152-703 (Republic of Korea), E-Mail
| |
Collapse
|
6
|
Assennato SM, Berzuini A, Foglieni B, Spreafico M, Allain JP, Prati D. Plasmodium genome in blood donors at risk for malaria after several years of residence in Italy. Transfusion 2014; 54:2419-24. [PMID: 24801273 DOI: 10.1111/trf.12650] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2013] [Revised: 02/17/2014] [Accepted: 02/17/2014] [Indexed: 11/28/2022]
Abstract
BACKGROUND At present, the main risk of transfusion-transmitted malaria (TTM) in nonendemic countries is chronic, asymptomatic immigrants from malaria-endemic areas. Semi-immune donors may carry undetected parasitemia. This study examines Plasmodium infection in at-risk blood donors in Northern Italy. STUDY DESIGN AND METHODS Plasma samples from 97 candidate donors and 80 controls were tested for malarial antibodies using a commercial enzyme immunoassay. The conserved 18S rRNA and the mitochondrial genes of Plasmodium were amplified to detect and quantify parasite genomes (copies/mL). Plasmodium species were identified with a species-specific nested polymerase chain reaction. Parasitemic samples were further tested by amplification of polymorphic repetitive regions in MSP-1 Block 2, MSP-2 Block 3, and glutamate-rich protein (GLURP) confirmed by sequencing. RESULTS Three of 83 seropositive (3.6%) and one of 14 seronegative at-risk candidate donors carried Plasmodium genome (4 × 10(3) -8.5 × 10(4) copies/mL): two P. falciparum, one P. malariae (seronegative sample), and one coinfection with P. malariae and P. ovale. Alleles of MSP-1 (MAD20 and K1), MSP-2 (3D7 and FC27), and GLURP were amplified from Sample 261. In Sample 282 only one allele in MSP-2 (FC27) and GLURP was amplified. No alleles were detected in Samples 283 and 331. CONCLUSIONS Immigrants from endemic countries might carry infectious Plasmodium after 2 to 5 years of continuous residence in Italy. Serologic screening may miss donors carrying P. malariae. Permanent exclusion or screening for both antibodies and genome are needed to prevent TTM.
Collapse
|
7
|
Nguyen ML, Goff T, Gibble J, Steele WR, Leiby DA. Analyzing actual risk in malaria-deferred donors through selective serologic testing. Transfusion 2012; 53:1736-43. [DOI: 10.1111/trf.12004] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2012] [Revised: 09/25/2012] [Accepted: 09/28/2012] [Indexed: 11/26/2022]
|
8
|
Faddy HM, Seed CR, Faddy MJ, Flower RL, Harley RJ. Malaria antibody persistence correlates with duration of exposure. Vox Sang 2012; 104:292-8. [PMID: 23134513 DOI: 10.1111/vox.12000] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND AND OBJECTIVES In Australia, the risk of transfusion-transmitted malaria is managed through the identification of 'at-risk' donors, antibody screening enzyme-linked immunoassay (EIA) and, if reactive, exclusion from fresh blood component manufacture. Donor management depends on the duration of exposure in malarious regions (>6 months: 'Resident', <6 months: 'Visitor') or a history of malaria diagnosis. We analysed antibody testing and demographic data to investigate antibody persistence dynamics. To assess the yield from retesting 3 years after an initial EIA reactive result, we estimated the proportion of donors who would become non-reactive over this period. MATERIALS AND METHODS Test results and demographic data from donors who were malaria EIA reactive were analysed. Time since possible exposure was estimated and antibody survival modelled. RESULTS Among seroreverters, the time since last possible exposure was significantly shorter in 'Visitors' than in 'Residents'. The antibody survival modelling predicted 20% of previously EIA reactive 'Visitors', but only 2% of 'Residents' would become non-reactive within 3 years of their first reactive EIA. CONCLUSION Antibody persistence in donors correlates with exposure category, with semi-immune 'Residents' maintaining detectable antibodies significantly longer than non-immune 'Visitors'.
Collapse
Affiliation(s)
- H M Faddy
- Research and Development, Australian Red Cross Blood Service, Brisbane, Qld, Australia.
| | | | | | | | | |
Collapse
|
9
|
Dubey A, Elhence P, Ghoshal U, Verma A. Seroprevalence of malaria in blood donors and multi-transfused patients in Northern India: Relevance to prevention of transfusion-transmissible malaria. Asian J Transfus Sci 2012; 6:174-8. [PMID: 22988385 PMCID: PMC3439759 DOI: 10.4103/0973-6247.98937] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Background: Transfusion-transmissible malaria (TTM) is a major concern in malaria endemic countries. A study was therefore conducted to know sero-prevalence of malaria in blood donors and the risk of TTM to multi-transfused patients at our hospital. Materials and Methods: Study subjects were: eligible blood donors (n = 1000), donors deferred due to history of fever in the last 3 months (n = 100), and multi-transfused patients (n = 200). Screening for malaria was done by slide microscopy, immunochromatographic rapid diagnostic test (RDT) for malaria antigen, and anti-malaria antibody by enzyme linked immunosorbent assay. Results: Malaria antibody prevalence in eligible donors and donors with history of fever, thalassemia patients, and in other multi-transfused patients was 16.9%, 22%, 6%, and 15%, respectively. None of the donors were positive for malaria on microscopic examination. None of the blood donors except one donor with history of fever, tested positive with RDT. Conclusion: Malaria antibody prevalence in blood donors at our center is high. As blood units donated by such donors have high-risk potential, special processing may be undertaken to reduce the risk of TTM.
Collapse
Affiliation(s)
- Anju Dubey
- Department of Transfusion Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
| | | | | | | |
Collapse
|
10
|
Jepsen MPG, Röser D, Christiansen M, Olesen Larsen S, Cavanagh DR, Dhanasarnsombut K, Bygbjerg I, Dodoo D, Remarque EJ, Dziegiel M, Jepsen S, Mordmüller B, Theisen M. Development and evaluation of a multiplex screening assay for Plasmodium falciparum exposure. J Immunol Methods 2012; 384:62-70. [PMID: 22835432 DOI: 10.1016/j.jim.2012.07.009] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2012] [Revised: 07/16/2012] [Accepted: 07/17/2012] [Indexed: 01/25/2023]
Abstract
Transfusion transmitted malaria (TTM) in non-endemic countries is reduced by questioning blood donors and screening of donated blood. Conventional screening is performed by Indirect Fluorescence Antibody Test (IFAT). This method is manual and difficult to standardize. Here we study the diagnostic performance of a multiplex assay for detection of antibodies against Plasmodium falciparum in donor blood using IFAT as a comparator. A multiplex assay (MPA) containing the antigens GLURP-R0, GLURP-R2, MSP3, MSP1 hybrid and AMA1 was constructed using xMAP® technology. A discrimination index for exposure to P. falciparum malaria was calculated by comparing travelers with clinical malaria (n=52) and non-exposed blood donors (n=119). The index was evaluated on blood donors with suspected malaria exposure (n=249) and compared to the diagnostic performance of IFAT. At a specificity of 95.8 %, the MPA discrimination index exhibited a diagnostic sensitivity of 90.4 % in travelers hospitalized with malaria. Percent agreement with IFAT was 92.3 %. Screening plasma from blood donors with suspected malaria exposure, we found 4.8 % to be positive by IFAT and 5.2 % by MPA with an agreement of 93.2 %. The calculated index from the MPA exhibits similar diagnostic performance as IFAT for detection of P. falciparum malaria. Combining the antibody response against multiple antigens in a discrimination index increased the sensitivity of the MPA and reduced the readout to a single value.
Collapse
|
11
|
Değirmenci A, Döşkaya M, Caner A, Nergis S, Gül K, Aydınok Y, Ertop T, Aksoy N, Korkmaz M, Alkan MZ, Üner A, Gürüz Y. Action plan to regain unnecessary deferred blood donors due to malaria risk in Turkey. Transfus Apher Sci 2012; 46:269-75. [PMID: 22464796 DOI: 10.1016/j.transci.2012.03.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2011] [Revised: 02/02/2012] [Accepted: 03/12/2012] [Indexed: 11/25/2022]
Abstract
Malaria was expected to be a major problem during blood donation in Turkey due to existence of malaria cases in southeastern region of Turkey. The present study aimed for the first time, to investigate malaria in "donors deferred for malaria risk" and to determine the regional rates of malaria deferral in Turkey. Blood samples were collected from several Blood Banks of southeastern provinces where local malaria cases still exist and from Blood Bank of Ege University Medical School (EUMS) located in western Turkey where malaria is eradicated decades ago. Plasmodium spp. and specific antibodies were investigated by stained smears, antigen detection, PCR and ELISA. Among the donors deferred for malaria risk, Plasmodium spp. were not detected by microscopy, PCR or antigen detection. Seroprevalances were 2% and 3.92% in western and southeastern regions, respectively. Rate of donor deferral for malaria risk was 0.9% in EUMS and deferrals were exclusively because of travel to southeastern Turkey. In southeastern provinces, deferrals were mainly due to malaria like fever history. The present study first time assessed regional rates of donor deferral due to malaria risk in Turkey. Previously, malaria was expected to be a major problem during blood donation in Turkey due to existence of malaria cases in southeastern region of Turkey. The results of the study showed that 97% of the deferrals were unnecessary. In conclusion, to reduce unnecessary donor deferrals in Turkey, in addition to comprehensive questioning for malaria history, the usage of a malaria antibody screening method should be initiated prior to deferral decision.
Collapse
Affiliation(s)
- Aysu Değirmenci
- Department of Parasitology, Ege University Medical School, Bornova/Izmir 35100, Turkey; Blood Bank of Ege University Medical School, Bornova/Izmir 35100, Turkey
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
O'Brien SF, Zou S, Laperche S, Brant LJ, Seed CR, Kleinman SH. Surveillance of transfusion-transmissible infections comparison of systems in five developed countries. Transfus Med Rev 2011; 26:38-57. [PMID: 21944935 PMCID: PMC7134890 DOI: 10.1016/j.tmrv.2011.07.001] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Most industrialized countries maintain surveillance programs for monitoring transmissible infection in blood donations, revising approaches to methodology and risk assessment as new threats emerge. A comparison of programs in the United States, Canada, France, the UK, and Australia indicates that they have similar function, although the structure of blood programs vary as does the extent and nature of formal ties with public health. The emergence of HIV in the late 1970s and early 1980s was key in recognizing that surveillance systems specific to blood transfusion were essential. Hence, most industrialized countries monitor transfusion-transmissible infections in donors and evaluate the impact of new testing and of predonation screening strategies. Emerging infections since HIV have had different transmission pathways and challenged blood programs to draw upon resources for a rapid and effective response, with recognition that the original focus on sexual/drug-related risk of HIV and hepatitis was inadequate. The focus of surveillance programs on new and emerging pathogens fulfills a key role in risk assessment and policy formulation. The precise nature of such activities varies by country because of the structure of the blood programs and surveillance systems, the strategic focus of the blood programs, and the epidemiology of disease in each country.
Collapse
Affiliation(s)
- Sheila F O'Brien
- National Epidemiology and Surveillance, Canadian Blood Services, 1800 Alta Vista Drive, Ottawa, Ontario, Canada K1G 4J5. sheila.o'
| | | | | | | | | | | |
Collapse
|
13
|
|
14
|
Detection of Plasmodium falciparum, P. vivax, P. ovale, and P. malariae merozoite surface protein 1-p19 antibodies in human malaria patients and experimentally infected nonhuman primates. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2010; 17:1631-8. [PMID: 20702658 DOI: 10.1128/cvi.00196-10] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Approximately 3.2 billion people live in areas where malaria is endemic, and WHO estimates that 350 to 500 million malaria cases occur each year worldwide. This high prevalence, and the high frequency of international travel, creates significant risk for the exportation of malaria to countries where malaria is not endemic and for the introduction of malaria organisms into the blood supply. Since all four human infectious Plasmodium species have been transmitted by blood transfusion, we sought to develop an enzyme-linked immunosorbent assay (ELISA) capable of detecting antibodies elicited by infection with any of these species. The merozoite surface protein 1 (MSP1), a P. falciparum and P. vivax vaccine candidate with a well-characterized immune response, was selected for use in the assay. The MSP1 genes from P. ovale and P. malariae were cloned and sequenced (L. Birkenmeyer, A. S. Muerhoff, G. Dawson, and S. M. Desai, Am. J. Trop. Med. Hyg. 82:996-1003, 2010), and the carboxyl-terminal p19 regions of all four species were expressed in Escherichia coli. Performance results from individual p19 ELISAs were compared to those of a commercial test (Lab 21 Healthcare Malaria enzyme immunoassay [EIA]). The commercial ELISA detected all malaria patients with P. falciparum or P. vivax infections, as did the corresponding species-specific p19 ELISAs. However, the commercial ELISA detected antibodies in 0/2 and 5/8 individuals with P. malariae and P. ovale infections, respectively, while the p19 assays detected 100% of individuals with confirmed P. malariae or P. ovale infections. In experimentally infected nonhuman primates, the use of MSP1-p19 antigens from all four species resulted in the detection of antibodies within 2 to 10 weeks postinfection. Use of MSP1-p19 antigens from all four Plasmodium species in a single immunoassay would provide significantly improved efficacy compared to existing tests.
Collapse
|
15
|
Seed CR, Coughlin JT, Pickworth AM, Harley RJ, Keller AJ. Relapsing vivax malaria despite chemoprophylaxis in two blood donors who had travelled to Papua New Guinea. Med J Aust 2010; 192:471-3. [PMID: 20402614 DOI: 10.5694/j.1326-5377.2010.tb03590.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2009] [Accepted: 12/16/2009] [Indexed: 11/17/2022]
Abstract
Two Australian blood donors were diagnosed with relapsing Plasmodium vivax malaria 5 and 15 months, respectively, after their most recent travel to a malaria-endemic country. Common features included travel to Papua New Guinea (specifically, the Kokoda Trail); full compliance with recommended malaria chemoprophylaxis; and negative results on malaria antibody testing at the time of donation. Although all fresh blood components from the two donors issued on the basis of these negative results were recalled before transfusion, these cases underscore the increased potential for relapse of P. vivax in donors returning from malaria-endemic countries, as well as the inability to identify the potential for relapse using current malarial screening tests.
Collapse
Affiliation(s)
- Clive R Seed
- Australian Red Cross Blood Service, Perth, WA, Australia.
| | | | | | | | | |
Collapse
|
16
|
Seed CR, Kee G, Wong T, Law M, Ismay S. Assessing the safety and efficacy of a test-based, targeted donor screening strategy to minimize transfusion transmitted malaria. Vox Sang 2010; 98:e182-92. [DOI: 10.1111/j.1423-0410.2009.01251.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
|
18
|
Allain JP, Stramer SL, Carneiro-Proietti ABF, Martins ML, Lopes da Silva SN, Ribeiro M, Proietti FA, Reesink HW. Transfusion-transmitted infectious diseases. Biologicals 2009; 37:71-7. [PMID: 19231236 DOI: 10.1016/j.biologicals.2009.01.002] [Citation(s) in RCA: 92] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2009] [Accepted: 01/09/2009] [Indexed: 01/12/2023] Open
Abstract
A spectrum of blood-borne infectious agents is transmitted through transfusion of infected blood donated by apparently healthy and asymptomatic blood donors. The diversity of infectious agents includes hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency viruses (HIV-1/2), human T-cell lymphotropic viruses (HTLV-I/II), Cytomegalovirus (CMV), Parvovirus B19, West Nile Virus (WNV), Dengue virus, trypanosomiasis, malaria, and variant CJD. Several strategies are implemented to reduce the risk of transmitting these infectious agents by donor exclusion for clinical history of risk factors, screening for the serological markers of infections, and nucleic acid testing (NAT) by viral gene amplification for direct and sensitive detection of the known infectious agents. Consequently, transfusions are safer now than ever before and we have learnt how to mitigate risks of emerging infectious diseases such as West Nile, Chikungunya, and Dengue viruses.
Collapse
|
19
|
Leiby DA, Nguyen ML, Notari EP. Impact of donor deferrals for malaria on blood availability in the United States. Transfusion 2008; 48:2222-8. [DOI: 10.1111/j.1537-2995.2008.01825.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
20
|
Abstract
PURPOSE OF REVIEW Blood safety is a topic of continuing concern, and much effort is expended on measures to decrease the risk for transmission of infectious agents via transfusion. At the same time, emerging infections may threaten this safety. A periodic review of risk is therefore appropriate. RECENT FINDINGS The risk for major transfusion transmissible infections continues to decline as a result of continually strengthening interventions and because of more general improvements in public health. More attention is being paid to emerging infections, and recently donor testing has been implemented for West Nile virus and Trypanosoma cruzi. Within the period covered by this review, the transmission of variant Creutzfeldt-Jakob disease by transfusion has been confirmed. Our understanding of other agents is improving. SUMMARY The estimated risk for transfusion transmitted hepatitis viruses and retroviruses is now vanishingly small, but clinicians should be alert to the possibility of infection with emerging infectious agents, because preventive measures may not be available in all cases.
Collapse
Affiliation(s)
- Roger Y Dodd
- Research and Development, American Red Cross, Rockville, Maryland 20855, USA.
| |
Collapse
|
21
|
Molecular diagnostic and surveillance tools for global malaria control. Travel Med Infect Dis 2007; 6:82-99. [PMID: 18342279 DOI: 10.1016/j.tmaid.2007.10.001] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2007] [Accepted: 10/09/2007] [Indexed: 01/09/2023]
Abstract
Malaria is the most devastating parasitic infection in the world, annually causing over 1 million deaths and extensive morbidity. The global burden of malaria has increased over the last several decades, as have rates of imported malaria into non-endemic regions. Rapid and accurate diagnostics are a crucial component of malaria control strategies, and epidemiological surveillance is required to monitor trends in malaria prevalence and antimalarial drug resistance. Conventional malaria diagnostic and surveillance tools can be cumbersome and slow with limitations in both sensitivity and specificity. New molecular techniques have been developed in an attempt to overcome these restrictions. These molecular techniques are discussed with regard to their technical advantages and disadvantages, with an emphasis on the practicality of implementation in malaria-endemic and non-endemic regions.
Collapse
|
22
|
Elghouzzi MH, Senegas A, Steinmetz T, Guntz P, Barlet V, Assal A, Gallian P, Volle P, Chuteau C, Beolet M, Berrebi S, Filisetti D, Doderer C, Abdelrahman T, Candolfi E. Multicentric evaluation of the DiaMed enzyme-linked immunosorbent assay malaria antibody test for screening of blood donors for malaria. Vox Sang 2007; 94:33-40. [PMID: 18021184 DOI: 10.1111/j.1423-0410.2007.00998.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND The risk of malaria transmission by blood transfusion is critical due to extensive travel from endemic areas to non-endemic areas. An enzyme-linked immunosorbent assay (ELISA) malaria antibody test has been developed that is claimed to perform better than the immunofluorescence assay test (IFAT). The assay contains antigens to both Plasmodium falciparum and Plasmodium vivax. A multicentre study was performed to evaluate the appropriateness of replacing the IFAT by the new ELISA test. MATERIAL AND METHODS Nine French blood banks participated in this multicentre study. Two panels of samples were evaluated. The first included 4163 samples from healthy donors and was used to calculate clinical specificity of the assay. The second involved 10,995 samples, either collected retrospectively or prospectively from malaria-risk donors , was used to assess the comparative performance of the ELISA and IFAT. Discordant samples were further tested using an in-house IFAT and also tested for presence of Plasmodium DNA by polymerase chain reaction. RESULTS The ELISA showed a clinical specificity of 99.02%. In the malaria-risk blood donors groups, the retrospective group showed a concordance rate of 92.6% (k = 0.90), while the prospective group showed a concordance rate of 97% (k = 0.46). After confirming the discordant sample results by an in-house IFAT, the k index increased to 0.81. None of the discordant samples was shown to contain Plasmodium DNA. CONCLUSION The performance of the ELISA test in this study has confirmed its potential as a new screening test for use in blood banks, as an alternative to the IFAT in prevention of transfusion-transmitted malaria in non-endemic countries.
Collapse
Affiliation(s)
- M-H Elghouzzi
- Etablissement Français du Sang Ile de France, 94150 Rungis, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Affiliation(s)
- David A Leiby
- Transmissible Diseases Department, American Red Cross Holland Laboratory, Rockville, Maryland 20855, USA.
| |
Collapse
|
24
|
She RC, Rawlins ML, Mohl R, Perkins SL, Hill HR, Litwin CM. Comparison of immunofluorescence antibody testing and two enzyme immunoassays in the serologic diagnosis of malaria. J Travel Med 2007; 14:105-11. [PMID: 17367480 DOI: 10.1111/j.1708-8305.2006.00087.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Serologic testing in malaria has traditionally been done by immunofluorescence antibody testing (IFA), but the use of commercially available enzyme immunoassays (EIAs) has become more widespread. METHODS We compared IFA with two commercial EIA kits, the Cellabs Pan Malaria CELISA and the Newmarket Malaria EIA. Seventy-five samples from 74 patients with clinically suspected malaria were examined by both EIA kits. The samples were also examined by IFA (n= 48) and/or Giemsa-stained blood smear (n= 48). RESULTS Using a consensus result as a gold standard, the agreement, sensitivity, and specificity were, respectively, as follows: Cellabs EIA 93.2, 95.5, and 92.2%; Newmarket EIA 87.7, 68.2, and 96.1%; and IFA 89.1, 86.4, and 91.7%. Compared to positive Giemsa-stained smears, the sensitivities were as follows: Cellabs EIA 90.9% (10/11), Newmarket EIA 54.5% (6/11), and IFA 100% (11/11). Antinuclear antibody (ANA)-positive sera (n= 11) and rheumatoid factor (RF)-positive sera (n= 11) showed no cross-reactivity with the Newmarket EIA, while the Cellabs EIA yielded positive results in one ANA-positive and two RF-positive sera. Among healthy blood donors (n= 50), the Newmarket EIA showed 100% specificity (50/50) and the Cellabs EIA showed a specificity of 92% (46/50). CONCLUSIONS While the Newmarket EIA was a generally more specific assay, it was insufficiently sensitive relative to the IFA and the Cellabs EIA for screening purposes for malaria antibodies. The Cellabs EIA demonstrated the best overall sensitivity and is a reasonable choice as a serodiagnostic tool for malaria. It may also be useful as an adjunct to Giemsa-stained smear examination, to aid in cases of low parasitemia in previously nonimmune individuals.
Collapse
Affiliation(s)
- Rosemary C She
- Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
| | | | | | | | | | | |
Collapse
|
25
|
A new ELISA kit which uses a combination of Plasmodium falciparum extract and recombinant Plasmodium vivax antigens as an alternative to IFAT for detection of malaria antibodies. Malar J 2007; 6:19. [PMID: 17313669 PMCID: PMC1819385 DOI: 10.1186/1475-2875-6-19] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2006] [Accepted: 02/21/2007] [Indexed: 11/30/2022] Open
Abstract
Background The methods most commonly used to measure malarial antibody titres are the Indirect Fluorescence Antibody Test (IFAT), regarded as the gold standard, and the Enzyme-Linked ImmunoSorbent Assay (ELISA). The objective here was to assess the diagnostic performance, i.e. the sensitivity and specificity, of a new malaria antibody ELISA kit in comparison to IFAT. This new ELISA kit, the ELISA malaria antibody test (DiaMed), uses a combination of crude soluble Plasmodium falciparum extract and recombinant Plasmodium vivax antigens. Methods Two groups were used: 95 samples from malaria patients to assess the clinical sensitivity and 2,152 samples from blood donors, who had not been exposed to malaria, to assess the clinical specificity. Results The DiaMed ELISA test kit had a clinical sensitivity of 84.2% and a clinical specificity of 99.6% as compared with 70.5% and 99.6% respectively, using the IFAT method. The ELISA method was more sensitive than the IFAT method for P. vivax infections (75% vs. 25%). However, in 923 malaria risk donors the analytical sensitivity of the ELISA test was 40% and its specificity 98.3%, performances impaired by large numbers of equivocal results non-concordant between ELISA and IFAT. When the overall analytical performances of ELISA was compared to IFAT, the ELISA efficiency J index was 0.84 versus 0.71 for IFAT. Overall analytical sensitivity was 93.1% and the analytical specificity 96.7%. Overall agreement between the two methods reached 0.97 with a reliability k index of 0.64. Conclusion The DiaMed ELISA test kit shows a good correlation with IFAT for analytical and clinical parameters. It may be an interesting method to replace the IFAT especially in blood banks, but further extensive investigations are needed to examine the analytical performance of the assay, especially in a blood bank setting.
Collapse
|
26
|
Abstract
Globalization may be viewed as the growing interdependence of countries worldwide through the increasing volume and variety of cross‐border transactions in goods and services, and also through the more rapid and widespread diffusion of technology. Globalization is not just an economic phenomenon, although it is frequently described as such, but includes commerce, disease and travel, and immigration, and as such it affects blood safety and supply in various ways. The relatively short travel times offered by modern aviation can result in the rapid spread of blood‐borne pathogens before measures to counteract transmission can be put in place; this would have happened with SARS if the basic life cycle of the SARS virus did not include an asymptomatic viraemia. This risk can be amplified by ecological factors which effect the spread of these pathogens once they are transferred to a naïve ecosystem, as happened with West Nile virus (WNV) in North America. The rationalization and contraction of the plasma products industry may be viewed as one aspect of globalization imposed by the remorseless inevitability of the market; the effect of this development on the safety and supply of products has yet to be seen, but the oversight and assurance of a shrinking number of players will present particular challenges. Similarly, the monopolization of technology, through patent enforcement which puts access beyond the reach of developing countries, can have an effect on blood safety. The challenges presented to blood safety by globalization are heightening the tensions between the traditional focus on the product safety – zero‐risk paradigm and the need to view the delivery of safe blood as an integrated process. As an illustration of this tension, donor deferral measures imposed by globalization‐induced risks such as vCJD and WNV have resulted in the loss of the safest and most committed portion of the blood donor population in many Western countries, leading to an increased risk to safety and supply. It is only through an appreciation of the basic needs of transfusion medicine, including the enunciation of appropriate principles to manage, rather than eliminate, risks, that the challenges imposed by globalization may be overcome.
Collapse
Affiliation(s)
- A Farrugia
- Blood and Tissues Unit, Australian Therapeutic Goods Administration, Woden, ACT, Australia
| |
Collapse
|
27
|
Seed CR, Hamzah J, Davis TME. Evidence for undetected malaria infection in non-immune Australian travellers not taking chemoprophylaxis. Acta Trop 2006; 99:62-6. [PMID: 16916494 DOI: 10.1016/j.actatropica.2006.07.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2006] [Revised: 06/29/2006] [Accepted: 07/05/2006] [Indexed: 11/17/2022]
Abstract
To determine whether travellers from malaria-free countries can develop unrecognised or asymptomatic malaria after visiting endemic areas, we analysed data from 751 prospective blood donors who had visited or resided in malaria-risk areas in the previous 3 years. Malarial antibodies were measured using an established commercial enzyme-linked immunoassay incorporating four recombinant blood-stage plasmodial antigens and with published sensitivity > or =83% and specificity 100%. Details of countries visited and antimalarial chemoprophylaxis used were obtained by questionnaire. Among the 606 subjects resident in malaria-free countries and with no past history of malaria, 176 had visited high-risk countries as categorised by the World Health Organisation (WHO). Of these, 89 took no chemoprophylaxis including 6 (6.7%) who were antibody-positive; there were no antibody-positive subjects in the 87 who took chemoprophylaxis (P=0.029), which was that recommended by WHO in 84% of cases. These data underscore the value of effective antimalarial prophylaxis in non-immune travellers visiting high malaria-risk areas but also suggest that unrecognised infections can occur in those unprotected by chemoprophylaxis.
Collapse
Affiliation(s)
- Clive R Seed
- Australian Red Cross Blood Service, 97 Great Eastern Highway Rivervale, Western Australia 6103, Australia.
| | | | | |
Collapse
|